Creatine has one of the most settled reputations in sports nutrition. It helps regenerate cellular energy, improves performance during repeated high-intensity efforts and can support gains from resistance training. Its biological role is familiar enough that a new claim can sound immediately plausible: if creatine supplies energy to immune cells, could it also help the body prevent cancer?
A recent mouse study has been interpreted in that direction. But the experiment did not test cancer prevention, and an even newer study points toward a very different possibility.
Together, the findings offer something more useful than a simple verdict on a supplement. They show why cancer biology rarely permits a nutrient to be labelled universally protective or harmful. Creatine can supply energy to immune cells that attack tumours. It may also change platelets or tumour cells in ways that help cancer spread. Which effect matters may depend on the cancer, disease stage, dose, delivery method and treatment context.
The study behind the “creatine fights cancer” story
In April 2026, UCLA-led researchers reported that creatine uptake helped dendritic cells maintain their energy and coordinate an antitumour immune response. Dendritic cells collect and present tumour antigens—the molecular clues that allow cancer-specific T cells to recognise a threat. Inside a tumour, where nutrients are scarce and immune function can become suppressed, that work is energetically demanding.
The researchers found that tumour-infiltrating dendritic cells increased expression of SLC6A8, the transporter used to bring creatine into cells. When that transporter was removed experimentally, the dendritic cells survived less well, showed weaker activation and were less effective at stimulating cancer-targeting T cells.
Adding creatine produced the opposite effect. It helped preserve intracellular ATP, supported inflammatory signalling and improved the cells’ ability to activate T cells. In mice bearing B16-OVA melanoma tumours, daily creatine treatment reduced tumour growth and increased the abundance and activation of type 1 conventional dendritic cells, an immune-cell population central to antitumour responses.
The study also included human cells. Dendritic cells derived from healthy donors became more immunologically active when treated with creatine in culture and were better able to stimulate engineered T cells against a cancer-associated antigen.
That is a coherent mechanism and a legitimate preclinical finding. It adds dendritic cells to earlier mouse research suggesting that creatine can support antitumour T cells and macrophages.
Why this was not a cancer-prevention study
Prevention asks whether an intervention reduces the chance that cancer begins in the first place. This study asked a different question: whether creatine could influence immune activity and growth after tumour cells had already been introduced.
The mice received one million engineered melanoma cells under the skin. Creatine injections began three days later, after tumour inoculation. The experiment therefore modelled treatment of an established experimental tumour—not prevention in healthy animals and not the natural development of melanoma over time.
The translation to ordinary supplementation is also uncertain. Mice received 10.5 milligrams per animal each day by intraperitoneal injection. For a typical laboratory mouse, that represents several hundred milligrams per kilogram delivered directly into the body rather than a three-to-five-gram oral maintenance dose in a human. The human-cell experiments used creatine concentrations created in a laboratory dish, not supplementation in patients.
The authors acknowledge another important limitation: the tumour experiment relied mainly on one subcutaneous, syngeneic B16-OVA melanoma model, with six mice in each treatment group. This model is valuable for studying antigen-specific immunity, but it cannot represent the biological diversity of human cancers.
The result is therefore best described as evidence that creatine metabolism can strengthen dendritic-cell function and slow tumour growth in one mouse model. It is not evidence that creatine prevents cancer in people.
Then a newer study found the opposite effect
In July 2026, researchers published a second paper in Nature Communications examining creatine, platelets and metastasis. Instead of focusing on immune cells inside a primary tumour, this team studied what happens when cancer cells enter the circulation and attempt to colonise another organ.
Platelets are best known for stopping bleeding, but they can also shelter circulating tumour cells from mechanical stress and immune surveillance. They may help those cells survive in the bloodstream and exit into distant tissues.
The researchers gave creatine orally to mice before injecting tumour cells into the circulation. Creatine made platelets more reactive and increased lung metastases in models using melanoma, colorectal, lung and breast cancer cells. In a spontaneous-metastasis melanoma model, supplementation also increased pulmonary metastasis and shortened survival.
Mechanistically, creatine entered platelet-producing megakaryocytes through SLC6A8. It increased creatine kinase B activity and altered STAT5B signalling, producing platelets with more activation-related receptors and granules. Removing the creatine transporter specifically from megakaryocytes, disrupting STAT5B or limiting platelet activation removed much of the metastasis-promoting effect.
The paper included a small human experiment: 11 healthy volunteers took 20 grams of creatine daily for 14 days. Their platelets became more reactive. But the volunteers did not have cancer, and the study did not observe cancer or metastasis in people. To test tumour-related effects, researchers isolated participant platelets and transferred them into immunocompromised mice together with melanoma cells. Platelets collected after creatine supplementation increased metastasis in that artificial mouse model.
This finding is concerning enough to justify further research, particularly in people with active or metastatic cancer. It is not proof that standard creatine use causes cancer or metastasis in humans.
How can creatine appear to help and harm?
The studies are not exact replications with opposite results. They examine different cells, different stages of cancer and different experimental systems.
In the first study, creatine supplied an energy buffer to dendritic cells inside a tumour. Better-supported dendritic cells activated T cells more effectively, strengthening immune pressure against the tumour.
In the second, creatine changed the biology of megakaryocytes and platelets. More reactive platelets helped circulating tumour cells survive and establish distant metastases.
Creatine may also act directly on malignant cells. A 2025 colorectal-cancer study reported that creatine promoted ferroptosis—an iron-dependent form of cell death—and improved the response to anti-PD-1 immunotherapy in mice. Other preclinical models have found that creatine metabolism can support tumour-cell energetics, motility or metastatic colonisation.
The common factor is energy and adaptation. Creatine does not know which cells we want to support. Immune cells, platelets, muscle and malignant cells can all use metabolic resources. The net effect is likely to depend on which cell population can access creatine, what signals are present and which stage of disease is being modelled.
What do studies in people tell us?
At present, human evidence is too limited to decide whether creatine improves or worsens cancer outcomes.
A 2026 systematic review identified five randomised trials involving 373 people with cancer. Most participants were receiving active treatment, and supplementation lasted between one and 12 weeks. These studies largely investigated muscle, body composition, physical function, quality of life and short-term safety—not tumour growth or metastasis.
The review found no clear difference in adverse events between creatine and placebo. Only one included trial reported overall survival and found no effect. That is mildly reassuring, but it is not enough to rule in benefit or rule out cancer-specific harm. The trials were small, heterogeneous and too short for many oncological outcomes.
Population studies add another layer without resolving causality. Analyses of US nutrition-survey data have associated higher estimated dietary creatine intake with slightly lower cancer prevalence. But these studies measured creatine mainly from foods such as meat and fish, often after a cancer diagnosis had already occurred. Diet can change following diagnosis, and creatine intake travels with many other nutritional, socioeconomic and behavioural factors. An association is not evidence that a creatine supplement prevents cancer.
What this means for someone taking creatine now
For healthy adults using creatine for training, muscle or healthy ageing, these mouse studies do not establish a need to stop. They did not demonstrate increased cancer incidence in people, and decades of human supplementation research have not identified cancer as a confirmed adverse effect.
They also provide no basis for starting creatine to prevent cancer. The strongest established benefits remain related to muscular energy, exercise performance and certain applications of resistance training—not cancer prevention.
The situation is different for someone living with cancer. Tumour type, metastatic status, platelet biology, treatment and nutritional needs may all matter. Creatine is being studied as a possible aid for muscle loss and as a potential partner to immunotherapy, but the clinical outcome data are not yet adequate. Anyone with active cancer should discuss creatine with the oncology team rather than adding or discontinuing it on the strength of a mouse headline.
The studies that would change the answer
The next step is not another general claim that creatine is anticancer or pro-cancer. Researchers need studies that separate primary-tumour control from metastatic risk, compare tumour types, use oral doses that reproduce realistic human exposure and test interactions with immunotherapy, chemotherapy, radiotherapy and antiplatelet medicines.
Prospective human trials would need to track tumour response, progression, metastasis, survival and thrombotic or bleeding outcomes—not only muscle strength and short-term tolerability. Biomarkers could help identify whether creatine primarily supports dendritic cells and T cells or produces unwanted platelet activation in a particular patient.
Until then, the responsible conclusion is deliberately unsatisfying: creatine is neither a proven cancer-prevention supplement nor a demonstrated human cancer risk. It is a biologically active nutrient whose effects inside cancer appear highly dependent on context.
The new mouse studies do not give us a supplement verdict. They give us a better question: which cells is creatine energising, at which stage of disease, and to whose advantage?